$0.02
(Market cap
$1 Mln
Recently Viewed
Clear AllMarket cap
$1 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-14 Mln
ROE
-1.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.4
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
6,328,750
CFO
$-123.12 Mln
EBITDA
$-127.78 Mln
Net Profit
$-190.94 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vyant Bio (VYNT)
| -72.3 | 9.3 | 16.2 | -71.9 | -75.7 | -65.7 | -60.5 |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Vyant Bio (VYNT)
| -89.6 | -51.3 | -53.5 | -17.2 | -86.9 | 37.0 | -59.1 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vyant Bio (VYNT)
|
0.2 | 1.2 | 0.2 | -13.7 | -6,688.4 | -- | -- | 0.1 |
| 74.9 | 9,733.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 43.4 | 17.1 | |
| 65.4 | 8,216.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 45.1 | 11,658.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 89.4 | 11,852.6 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 8,209.1 | 1,396.6 | 316.9 | 59.8 | 153.6 | 27.1 | 161.7 | |
| 520.8 | 12,204.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.3 | |
| 415.6 | 14,867.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.4 | |
| 107.2 | 8,460.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.8 | |
| 339.3 | 9,538.9 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease,... scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey. Read more
Pres, CEO & Director
Mr. John A. Roberts M.B.A., MBA
Pres, CEO & Director
Mr. John A. Roberts M.B.A., MBA
Headquarters
Cherry Hill, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Vyant Bio Inc (VYNT) is $0.19 (NASDAQ) as of 29-Dec-2023 15:40 EDT. Vyant Bio Inc (VYNT) has given a return of -75.72% in the last 3 years.
Since, TTM earnings of Vyant Bio Inc (VYNT) is negative, P/E ratio is not available.
The P/B ratio of Vyant Bio Inc (VYNT) is 0.12 times as on 29-Dec-2023, a 97 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.18
|
0.41
|
|
2021
|
-0.17
|
0.25
|
|
2020
|
-1.75
|
-0.44
|
|
2019
|
-1.87
|
1.70
|
|
2018
|
-0.02
|
0.06
|
The 52-week high and low of Vyant Bio Inc (VYNT) are Rs -- and Rs -- as of 25-Apr-2026.
Vyant Bio Inc (VYNT) has a market capitalisation of $ 1 Mln as on 29-Dec-2023. As per SEBI classification, it is a company.
Before investing in Vyant Bio Inc (VYNT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.